Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H32N2.2ClH |
| Molecular Weight | 361.393 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.C(C1CC1)N2CC3CN(CC4CC4)CC(C2)C35CCCC5
InChI
InChIKey=NXXZICGFHYJPGE-UHFFFAOYSA-N
InChI=1S/C19H32N2.2ClH/c1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16;;/h15-18H,1-14H2;2*1H
| Molecular Formula | C19H32N2 |
| Molecular Weight | 288.4708 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tedisamil is an antiarrhythmic with additional anti-ischaemic properties, which acts via potassium channel blockade. This drug can be categorised as a class III antiarrhythmic agent due to its effects of action potential and QT interval prolongation in these patients. Although tedisamil has been shown to be an effective anti-ischaemic agent, with Phase III trials for angina pectoris now completed, the company are now pursuing the use of tedisamil for the treatment of atrial fibrillation, for which tedisamil is still in Phase II/III clinical trials. The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted not to recommend approval for Solvay Pharmaceuticals’ investigational anti-arrhythmic drug Pulzium (Tedisamil) and asked the company to give the FDA more information.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7. | 1998 Mar 6 |
|
| Dispersion of cell-to-cell uncoupling precedes low K+-induced ventricular fibrillation. | 2001 |
|
| Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence. | 2001 Apr |
|
| Tedisamil (Solvay). | 2001 Jan |
|
| Tedisamil: master switch of nature? | 2001 Jan |
|
| Effects of tedisamil on cardiovascular tissues isolated from normo- and hypertensive rats. | 2001 Jul |
|
| Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part II: Pharmacological profile. | 2001 May |
|
| Newer antiarrhythmic drugs. | 2001 May-Jun |
|
| Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models. | 2001 Oct |
|
| New antiarrhythmic drugs for the treatment of atrial fibrillation. | 2002 Feb |
|
| Tedisamil blocks BK-type Ca(2+)-dependent K(+) channels and modulates action potentials in rat hippocampal neurons. | 2002 Feb 15 |
|
| Bertosamil blocks HERG potassium channels in their open and inactivated states. | 2002 Sep |
|
| Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischaemia-induced arrhythmias in rats. | 2003 Aug |
|
| Modulation of intracellular Ca(2+) concentration by tedisamil, a class III antiarrhythmic agent, in isolated heart preparation. | 2003 Aug 22 |
|
| Tedisamil in coronary disease: additional benefits in the therapy of atrial fibrillation? | 2003 Jun |
|
| Antiarrhythmic drug therapy of atrial fibrillation: focus on new agents. | 2003 Jun |
|
| Atrial fibrillation: emerging possibilities for drug treatment: an overview of current opportunities and recent developments. | 2003 Jun |
|
| Role of atrial fibrillation threshold evaluation on guiding treatment. | 2003 Oct 1 |
|
| Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. | 2004 |
|
| Trial finds new anti-arrhythmic, tedisamil, is superior to placebo for converting recent onset atrial fibrillation or atrial flutter. | 2004 Dec |
|
| Effect of the antifibrillatory compound tedisamil (KC-8857) on transmembrane currents in mammalian ventricular myocytes. | 2004 Dec |
|
| Tedisamil: a new novel antiarrhythmic. | 2004 Feb |
|
| Theoretical possibilities for the development of novel antiarrhythmic drugs. | 2004 Jan |
|
| Role of pharmacotherapy in Brugada syndrome. | 2004 Jan 1 |
|
| Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. | 2004 Jul 7 |
|
| Tedisamil attenuates foetal transformation of myosin in the hypertrophied rat myocardium. | 2004 Nov |
|
| Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. | 2005 Jan 1 |
|
| Do we need pharmacological therapy for atrial fibrillation in the ablation era? | 2006 Dec |
|
| Approach to the asymptomatic patients with Brugada syndrome. | 2007 Apr 1 |
|
| New antiarrhythmic treatment of atrial fibrillation. | 2007 Jul |
|
| Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. | 2008 |
|
| Update on atrial fibrillation: part II. | 2008 Mar |
|
| New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? | 2008 Sep 22 |
|
| Recent advances in pharmacotherapy of atrial fibrillation. | 2009 Aug |
|
| Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil. | 2009 Aug |
|
| The transmembrane beta-subunits KCNE1, KCNE2, and DPP6 modify pharmacological effects of the antiarrhythmic agent tedisamil on the transient outward current Ito. | 2009 Jun |
|
| Clinically important interaction between tedisamil and verapamil. | 2009 May |
|
| Atrial fibrillation: from ion channels to bedside treatment options. | 2009 Nov-Dec |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:29:48 GMT 2023
by
admin
on
Fri Dec 15 15:29:48 GMT 2023
|
| Record UNII |
S5O682VL3K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
132523-84-3
Created by
admin on Fri Dec 15 15:29:48 GMT 2023 , Edited by admin on Fri Dec 15 15:29:48 GMT 2023
|
PRIMARY | |||
|
11566690
Created by
admin on Fri Dec 15 15:29:48 GMT 2023 , Edited by admin on Fri Dec 15 15:29:48 GMT 2023
|
PRIMARY | |||
|
S5O682VL3K
Created by
admin on Fri Dec 15 15:29:48 GMT 2023 , Edited by admin on Fri Dec 15 15:29:48 GMT 2023
|
PRIMARY | |||
|
m10516
Created by
admin on Fri Dec 15 15:29:48 GMT 2023 , Edited by admin on Fri Dec 15 15:29:48 GMT 2023
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |